We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
CEA Grants Roche License to Patent that Covers a Process for Synthesis of dsRNA
News

CEA Grants Roche License to Patent that Covers a Process for Synthesis of dsRNA

CEA Grants Roche License to Patent that Covers a Process for Synthesis of dsRNA
News

CEA Grants Roche License to Patent that Covers a Process for Synthesis of dsRNA

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "CEA Grants Roche License to Patent that Covers a Process for Synthesis of dsRNA"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

The CEA has announced that its life science division has granted Roche Diagnostics GmbH, (Mannheim, Germany) a non-exclusive license under the patent family EP10618966.

This license concerns some RNAi products that Roche Diagnostics GmbH supplies to its customers in the research reagent field.

This patent family, owned solely by the CEA, covers a process for an enzymatic synthesis of double-stranded RNA based on the transcription of a double-stranded DNA template.

Double-stranded RNA triggers different types of gene silencing named RNA silencing or RNA interference. The application of RNA interference in mammals has the potential to allow therapeutic gene silencing.

Advertisement